Strong H1 2025 results with double-digit CER growth in revenue and EBITDA, driven by robust commercial pharma and manufacturing performance. Strategic progress in GLP-1, insulin, and vaccine manufacturing positions the business for sustained growth, despite currency and tax headwinds.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.